Nevertheless, targeting signaling pathways activated in canine and human MM, such as Ras/MAPK and PI3K/AKT/mTOR, remain a viable option due to their frequent activation and vital role in supporting tumor growth [4,23]. This evidence concerns the gene MTOR and Miyoshi myopathy.